Results 51 to 60 of about 86,323 (286)
Biosensors, 2023 This work reports the development of a fluorescence method for the detection of poly(ADP-ribose) polymerase-1 (PARP1), in which a phenylboronic acid-modified fluorescein isothiocyanate dye (FITC-PBA) was used to recognize the formed poly(ADP-ribose) (PAR)
Fengli Gao +4 more
doaj +1 more source
Mechanisms of poly(ADP‐ribose) polymerase catalysis; mono‐ADP‐ribosylation of poly(ADP‐ribose) polymerase at nanomolar concentrations of NAD [PDF]
FEBS Letters, 1986 Calf thymus and rat liver poly(ADP‐ribose) polymerase enzymes, and the polymerase present in extracts of rat liver nuclei synthesize unstable mono‐ADP‐ribose protein adducts at 100 nM or lower NAD concentrations. The isolated enzyme‐mono‐ADP‐ribose adduct hydrolyses to ADP‐ribose and enzyme protein at pH values slightly above 7.0 indicating a ...
Bauer, Pal I. +2 more
openaire +2 more sources
Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks
Nature Communications, 2019 PARP-1 is rapidly recruited and activated by DNA double-strand breaks (DSBs). Upon activation, PARP-1 synthesizes a structurally complex polymer composed of ADP-ribose units that facilitates local chromatin relaxation and the recruitment of DNA repair ...
Marie-christine Caron +14 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Neoplasia: An International Journal for Oncology Research, 2014 Poly(ADP-ribose) polymerase-1 (PARP1) catalyzes the poly(ADP-ribosyl)ation of protein acceptors using NAD+ as the substrate is now considered as an important target for development of anticancer therapy. PARP1 is known to be post-translationally modified
Lianhua Piao +6 more
doaj +1 more source
DNA damage in Nijmegen Breakage Syndrome cells leads to PARP hyperactivation and increased oxidative stress. [PDF]
PLoS Genetics, 2012 Nijmegen Breakage Syndrome (NBS), an autosomal recessive genetic instability syndrome, is caused by hypomorphic mutation of the NBN gene, which codes for the protein nibrin.
Harald Krenzlin +6 more
doaj +1 more source
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Drugs in R&D, 2020 Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and ...
S. Boussios +8 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Cancers, 2018 Inhibition of poly(ADP-ribose) polymerase (PARP) activity induces synthetic lethality in mutated BRCA1/2 cancers by selectively targeting tumor cells that fail to repair DNA double strand breaks (DSBs). Clinical studies have confirmed the validity of the
I. Faraoni, G. Graziani
semanticscholar +1 more source
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source